Research Analysts’ Weekly Ratings Updates for Rapport Therapeutics (RAPP)

Several analysts have recently updated their ratings and price targets for Rapport Therapeutics (NASDAQ: RAPP):

• 3/11/2026 – Rapport Therapeutics had its price target raised by Wells Fargo & Company from $43.00 to $46.00. They now have an “overweight” rating on the stock.
• 3/10/2026 – Rapport Therapeutics had its “market outperform” rating reaffirmed by Citigroup Inc..
• 3/9/2026 – Rapport Therapeutics had its price target raised by BTIG Research to $47.00. They now have a “buy” rating on the stock.
• 3/9/2026 – Rapport Therapeutics had its “buy” rating reaffirmed by TD Cowen.
• 2/28/2026 – Rapport Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 2/7/2026 – Rapport Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 2/2/2026 – Rapport Therapeutics is now covered by Wells Fargo & Company. They set an “overweight” rating and a $43.00 price target on the stock.
• 1/25/2026 – Rapport Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 1/22/2026 – Rapport Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 1/17/2026 – Rapport Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.

Insider Activity

In other news, CEO Abraham Ceesay sold 5,833 shares of Rapport Therapeutics stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $29.34, for a total transaction of $171,140.22. Following the completion of the sale, the chief executive officer directly owned 556,247 shares in the company, valued at $16,320,286.98. The trade was a 1.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider David Bredt sold 8,500 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $29.02, for a total transaction of $246,670.00. Following the completion of the transaction, the insider directly owned 387,075 shares of the company’s stock, valued at approximately $11,232,916.50. This represents a 2.15% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 69,669 shares of company stock valued at $1,999,877 in the last three months. 13.57% of the stock is currently owned by corporate insiders.

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.